1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Fibromyalgia - US Drug Forecast and Market Analysis to 2023

Fibromyalgia - US Drug Forecast and Market Analysis to 2023

  • May 2015
  • 134 pages
  • ID: 4188645
In this report:
GLOBALDATA ESTIMATED THAT GABAPENTIN GENERICS GENERATED SALES OF APPROXIMATELY $##.##M FOR FIBROMYALGIA IN 2013, WHICH IS EXPECTED TO DROP TO $##.##M IN 2023, AT A NEGATIVE CAGR OF ##.##%.
IN 2013, IT WAS ESTIMATED THAT OPIOID GENERICS GARNERED $##.##M GLOBALLY, WHICH IS EXPECTED TO DECLINE TO $##.##M BY 2023, AT A NEGATIVE CAGR OF ##.##%.

Summary

Table of Contents

Search Inside

Fibromyalgia - US Drug Forecast and Market Analysis to 2023

Brief

The fibromyalgia market is relatively additional and not yet established. Three drugs currently dominate the sales across the 7MM and form the core treatment options; Lyrica, Cymbalta and Savella are all approved in the U.S. while only the former is approved in Japan (JP). Since these drugs are also available in the 5EU for other indications, they are prescribed as off-label therapies. A handful of other genericized products also provide off-label usage including antidepressants, anti-epileptics, opioids and muscle relaxants. Although Lyrica, Cymbalta and Savella can provide an effective treatment regimen, there are ample opportunities for the development of alternative treatment choices which can expand the medications available to patients, providing improvement in efficacy, safety and compliance. By 2023, there will be four additional entrants to the market (Lyrica CR, TNX-102 SL, DS-5565 and TD-9855). These additional products will help to drive market increase and offset some of the patent expiries of the leading brands during the forecast period. Despite these advancements in the treatment landscape, fibromyalgia therapeutic sales growth are anticipated to be minimal.

The US fibromyalgia market is the biggest in the 7MM, owing to its big population size and high drug prices. Cymbalta was the top-selling fibromyalgia brand in the U.S. in 2013, accounting for nearly 41.0 percent of the US market with $600.4m in sales. Its strong position was supported by the combination of its efficacy and tolerability profile. However, Cymbalta will lose its leading position due to the sharp generic erosion triggered by its US patent expiry in December 2013.

Overview

- Overview of Fibromyalgia including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the challenging landscape.

- Exhaustive information on the top drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the best drugs in the U.S. from 2013-2023.

- Analysis of the impact of main events as well the drivers and restraints affecting the US Fibromyalgia market.

Great reasons to purchase

- Understand and capitalize by identifying products that are most likely to ensure a strong return

- Stay ahead of the competition by understanding the changing ambitious landscape for Fibromyalgia.

- Effectively plan your M&A and partnership strategies by identifying drugs with the most favorable sales plausible

- Make more informed business decisions from insightful and detailed analysis of drug performance

- Obtain sales forecast for drugs from 2013-2023 in the US.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Nicolas helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026

Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026

  • $ 10995
  • Industry report
  • June 2018
  • by GlobalData

Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026SummaryDry Eye Syndrome (DES) is a multifactorial disease of the tears and ocular surface that causes ocular discomfort, visual disturbances, ...

Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027

Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027

  • $ 10995
  • Industry report
  • June 2018
  • by GlobalData

Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027SummaryFor nearly two decades, the Cytomegalovirus (CMV) therapeutics landscape has been dominated by ganciclovir and valganciclovir, with ...

Gene Therapy in Oncology

Gene Therapy in Oncology

  • $ 7995
  • Industry report
  • June 2018
  • by GlobalData

Gene Therapy in OncologySummaryGene therapy refers to any procedure that aims to treat or alleviate a disease by genetically modifying the cell of a patient. The material to be transferred may consist ...


ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on